Anticoagulation in hemodialysis: A narrative review.
Journal
Seminars in dialysis
ISSN: 1525-139X
Titre abrégé: Semin Dial
Pays: United States
ID NLM: 8911629
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
14
07
2020
revised:
28
09
2020
accepted:
11
10
2020
pubmed:
3
11
2020
medline:
29
10
2021
entrez:
2
11
2020
Statut:
ppublish
Résumé
Systemic anticoagulation in maintenance hemodialysis (HD) has historically been considered necessary to maintain the extracorporeal circuit (ECC) and preserve dialysis efficiency. Unfractionated heparin (UFH) is the most commonly used anticoagulant due to low cost and staff familiarity. Despite widespread use, there is little standardization of heparin dosing protocols in the United States. Although the complication rates with UFH are low for the general population, certain contraindications have led to exploration in alternative anticoagulants in patients with end-stage kidney disease (ESKD). Here we review the current evidence regarding heparin dosing protocols, complications associated with heparin use, and discuss alternatives to UFH including anticoagulant-free routine HD.
Substances chimiques
Anticoagulants
0
Heparin
9005-49-6
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
103-115Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Daugirdas JT, Blake PG, Ing TS. Chapter 14: anticoagulation. In: Handbook of Dialysis. 5th edn. Philadelphia, Penn: Wolters Kluwer 2014:254-255.
Swartz R. Hemorrhage during high-risk hemodialysis using controlled heparinization. Nephron. 1981;28(2):65-69.
Swartz RD, Port FK. Preventing hemorrhage in high-risk hemodialysis: regional versus low-dose heparin. Kidney Int. 1979;16(4):513-518.
Craddock PR, Fehr J, Brigham KL, Kronenberg RS, Jacob HS. Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. N Engl J Med. 1977;297(14):769-774.
Hakim RM, Breillatt J, Lazarus J, Port FK. Complement activation and hypersensitivity reactions to dialysis membranes. N Engl J Med. 1984;311(14):878-882.
Boyer CJ, Swartz RD. Severe clotting during extracorporeal dialysis procedures. Semin Dial. 1991;4(2):69-71.
Davenport A. Review article: low-molecular-weight heparin as an alternative anticoagulant to unfractionated heparin for routine outpatient haemodialysis treatments. Nephrology. 2009;14(5):455-461.
Davenport A. What are the anticoagulation options for intermittent hemodialysis? Nat Rev Nephrol. 2011;7(9):499-508.
Knudson F, Nielsen A. Polycarbonate versus cuprophan dialyzers: effect on platelet function. Blood Purif. 1984;2(3):173-180.
Schmitt G, Moake J, Rudy C, Vicks S, Hamburger R. Alterations in hemostatic parameters during hemodialysis with dialyzers of different membrane composition and flow design. Platelet activation and factor VIII-related Von Willebrand factor during hemodialysis. Am J Med. 1987;83(3):411-418.
Docci D, Turchi F, Del Vecchio C, Bilancioni R, Cenciotti L, Pretolani E. Hemodialysis-associated platelet loss: study of the relative contribution of dialyzer membrane composition and geometry. Int J Artif Organs. 1984;7(6):337-340.
Sreeharan N, Crow M, Salter M, Donaldson D, Rajah S, Davison A. Membrane effect on platelet function during hemodialysis: a comparison of cuprophan and polycarbonate. Artif Organs. 1982;6(3):324-327.
Berrettini M, Buoncristiani U, Parise P, Ballatori E, Nenci G. Polyacrilonytrile versus cuprophan membranes for hemodialysis: evaluation of efficacy and biocompatibility by platelet aggregation studies. Int J Artif Organs. 1981;4(5):219-222.
Moll S, De Moerloose P, Reber G, Schifferli J, Leski M. Comparison of two hemodialysis membranes, polyacrylonitrile and cellulose acetate, on complement and coagulation systems. Int J Artif Organs. 1990;15(3):273-279.
Bjornson J. Thrombus formation in the artificial kidney. Platelet and fibrin(ogen) content of experimental thrombi detected by radioisotope technique. Scand J Urol Nephrol. 1978;12(3):251-257.
Cameron JS. Practical haemodialysis began with cellophane and heparin: The crucial role of William Thalhimer (1884-1961). Nephrol Dial Transplant. 2000;15(7):1086-1091. https://doi.org/10.1093/ndt/15.7.1086
Elliott MJ, Zimmerman D, Holden RM. Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates. Am J Kidney Dis. 2007;50(3):433-440.
Krivitski NM, Kislukhin VV, Snyder JW, et al. In vivo measurement of hemodialyzer fiber bundle volume: theory and validation. Kidney Int. 1998;54(5):1751-1758.
Ross EA, Paugh-Miller JL, Nappo RW. Interventions to improve hemodialysis adequacy: protocols based on real-time monitoring of dialysate solute clearance. Clin Kidney J. 2018;11(3):394-399.
Vanommeslaeghe F, Van Biesen W, Dierick M, Boone M, Dhondt A, Eloot S. Micro-computed tomography for the quantification of blocked fibers in hemodialyzers. Sci Rep. 2018;8(2677):1-9.
Vanommeslaeghe F, De Somer F, Josipovic I, et al. Evaluation with micro-CT of different anticoagulation strategies during hemodialysis in patients with thrombocytopenia: a randomized crossover study. Artif Organs. 2019;43:756-763.
Derbalah A, Duffull S, Newall F, Moynihan K, Al SH. Revisiting the pharmacology of unfractionated heparin. Clin Pharmacokinet. 2019;58:1015-1028.
Davenport A. The rationale for the use of low molecular weight heparin for hemodialysis treatments. Hemodial Int. 2013;17(SUPPL1):28-32.
Chandarajoti K, Liu J, Pawlinski R. The design and synthesis of new synthetic low molecular weight heparins. J Thromb Haemost. 2016;14(6):1135-1145.
Wilhelmsson S, Lins L. Heparin elimination and hemostasis in hemodialysis. Clin Nephrol. 1984;22(6):303-306.
Brunet P, Simon N, Opris A, et al. Pharmacodynamics of unfractionated heparin during and after a hemodialysis session. Am J Kidney Dis. 2008;51(5):789-795.
McAvoy TJ. Pharmacokinetic modeling of heparin and its clinical implications. J Pharmacokinet Biopharm. 1979;7(4):331-354.
Ashby D, Borman N, Burton J, et al. Renal association clinical practice guideline on haemodialysis. BMC Nephrol. 2019;20(1). https://doi.org/10.1186/s12882-019-1527-3
European Best Practice Guideline. V.2 Prevention of clotting in the HD patient with normal bleeding risk. Nephrol Dial Transplant. 2002;17:64-66. https://doi.org/10.1093/ndt/17.suppl_7.64
Shen JI, Montez-Rath ME, Mitani AA, Erickson KF, Winkelmayer WC. Correlates and variance decomposition analysis of heparin dosing for maintenance hemodialysis in older U.S. patients. Pharmacoepidemiol Drug Saf. 2014;23(5):515-525.
Davenport A. Optimization of heparin anticoagulation for hemodialysis. Hemodial Int. 2011;15(SUPPL. 1):43-48.
Murea M, Russell GB, Daeihagh P, et al. Efficacy and safety of low-dose heparin in hemodialysis. Hemodial Int. 2018;22(1):74-81.
Shen JI, Winkelmayer WC. Use and safety of unfractionated heparin for anticoagulation during maintenance hemodialysis. Am J Kidney Dis. 2012;60(3):473-486.
Smythe MA, Koerber JM, Westley SJ, et al. Use of the activated partial thromboplastin time for heparin monitoring. Am J Clin Pathol. 2001;115(1):148-155.
Hattersley PG. Activated coagulation time of whole blood. J Am Med Assoc. 1966;196(5):436-440.
Congdon JE, Karinal CG, Wallin JD. Monitoring heparin therapy in hemodialysis. JAMA. 1973;226(13):1529-1533.
Mehta R. Anticoagulation during continuous renal replacement therapy. ASAIO J. 1994;40(4):931-935.
Wilhelmsson S, Lins L. Whole-blood activated coagulation time for evaluation of heparin activity during hemodialysis: a comparison of administration by single-dose and by infusion. Clin Nephrol. 1983;19(2):82-86.
Nadarajah L, Fan S, Forbes S, Ashman N. Major bleeding in hemodialysis patients using unfractionated or low molecular weight heparin: a single-center study. Clin Nephrol. 2015;84(5):274-279.
Shen JI, Mitani AA, Winkelmayer WC. Heparin use in hemodialysis patients following gastrointestinal bleeding. Am J Nephrol. 2014;40(4):300-307.
Brunelli SM, Cohen DE, Marlowe G, et al. Safety and efficacy of heparin during dialysis in the context of systemic anticoagulation and antiplatelet medications. J Nephrol. 2019;32:453-460.
Lin MC, Streja E, Soohoo M, et al. Warfarin use and increased mortality in end stage renal disease. Am J Nephrol. 2017;46(4):249-256.
Syed S, Reilly RF. Heparin-induced thrombocytopenia: a renal perspective. Nat Rev Nephrol. 2009;5(9):501-511.
Hutchison CA, Dasgupta I. National survey of heparin-induced thrombocytopenia in the haemodialysis population of the UK population. Nephrol Dial Transplant. 2007;22(6):1680-1684.
Yamamoto S, Koide M, Matsuo M, et al. Heparin-induced thrombocytopenia in hemodialysis patients. Am J Kidney Dis. 1996;28(1):82-85.
Matsuo T. Heparin-induced thrombocytopenia and hemodialysis. J Blood Disord Transfus. 2013;s2. https://doi.org/10.4172/2155-9864.S2-002
Matsuo T, Matuo M, Wanaka K, Sakai R. Heparin re-exposure after heparin-induced thrombocytopenia in a chronic hemodialysis patient. Clin Lab Haem. 2003;25:333-334.
Matsuo T, Kobayashi H, Matsuo M, et al. Frequency of anti-heparin-PF4 complex antibodies (HIT antibodies) in uremic patients on chronic intermittent hemodialysis. Pathophysiol Haemost Thromb. 2006;35(6):445-450.
Matsuo T, Kusano H, Wanaka K, Ishihara M, Oyama A. Heparin-induced thrombocytopenia in a uremic patient requiring hemodialysis: an alternative treatment and reexposure to heparin. Clin Appl Thromb. 2007;13(2):182-187.
Wanaka K, Matsuo T, Matsuo M, et al. Re-exposure to heparin in uremic patients requiring hemodialysis with heparin-induced thrombocytopenia. J Thromb Haemost. 2010;8(3):616-618.
O'Shea SI, Sands JJ, Nudo SA, Ortel TL. Frequency of anti-heparin-platelet factor 4 antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosis. Am J Hematol. 2002;69(1):72-73.
Greinacher A, Zinn S, Wizemann BUW. Heparin-induced antibodies as a risk factor for thromboembolism and haemorrhage in patients undergoing chronic haemodialysis. Lancet. 1996;348(9029):764.
Asmis LM, Segal JB, Plantinga LC, et al. Heparin-induced antibodies and cardiovascular risk in patients on dialysis. Thromb Haemost. 2008;100(3):498-504.
Liu CC, Chou LP, Chen TS, Chen CA, Tsai YF. Significant association of anti-platelet factor 4/heparin antibody with cardiovascular disease in hemodialysis patients: a longitudinal 7-year study. Int Urol Nephrol. 2018;50(12):2289-2297.
Krane V, Berger M, Lilienthal J, Winkler K, Schambeck C, Wanner C. Antibodies to platelet factor 4-heparin complex and outcome in hemodialysis patients with diabetes. Clin J Am Soc Nephrol. 2010;5(5):874-881.
Sitter T, Spannagl M, Banas B, Schiffl H. Prevalence of heparin-induced PF4-heparin antibodies in hemodialysis patients. Nephron. 1998;79(2):245-246.
Palomo I, Pereira J, Alarcón M, et al. Prevalence of heparin-induced antibodies in patients with chronic renal failure undergoing hemodialysis. J Clin Lab Anal. 2005;19(5):189-195.
Maharaj S, Chang S, Seegobin K, et al. Temporality of heparin-induced antibodies: a retrospective study in outpatients undergoing hemodialysis on unfractionated heparin. Exp Hematol Oncol. 2018;7(1):1-9.
Carrier M, Knoll GA, Kovacs MJ, Moore JC, Fergusson D, Rodger MA. The prevalence of antibodies to the platelet factor 4-heparin complex and association with access thrombosis in patients on chronic hemodialysis. Thromb Res. 2007;120(2):215-220.
Carrier M, Rodger MA, Fergusson D, et al. Increased mortality in hemodialysis patients having specific antibodies to the platelet factor 4-heparin complex. Kidney Int. 2008;73(2):213-219.
Shavit L, Bar-Lev M, Lifschitz M, Fink D, Rudensky B, Slotki I. Prevalence and clinical significance of heparin induced antibodies in chronic hemodialysis patients and cardiac surgery patients. Int J Artif Organs. 2011;34(12):1172-1178.
Mureebe L, Coats RD, Silliman WR, Shuster TA, Nichols WK, Silver D. Heparin-associated antiplatelet antibodies increase morbidity and mortality in hemodialysis patients. Surgery. 2004;136(4):848-853.
de la Vega LP, Miller RS, Benda MM, et al. Association of heparin-dependent antibodies and adverse outcomes in hemodialysis patients: a population-based study. Mayo Clin Proc. 2005;80(8):995-1000.
Williams RT, Damaraju LV, Mascelli MA, et al. Anti-platelet factor 4/heparin antibodies: an independent predictor of 30-day myocardial infarction after acute coronary ischemic syndromes. Circulation. 2003;107(18):2307-2312.
Chan MK, Persaud J, Varghese Z, Moorhead JF. Pathogenic roles of post-heparin lipases in lipid abnormalities in hemodialysis patients. Kidney Int. 1984;25(5):812-818.
Näsström B, Stegmayr B, Gupta J, Olivecrona G, Olivecrona T. A single bolus of a low molecular weight heparin to patients on haemodialysis depletes lipoprotein lipase stores and retards triglyceride clearing. Nephrol Dial Transplant. 2005;20:1172-1179.
Streja E, Gosmanova EO, Molnar MZ, et al. Association of continuation of statin therapy initiated before transition to chronic dialysis therapy with mortality after dialysis initiation. JAMA Netw Open. 2018;1(6):e182311.
Soohoo M, Moradi H, Obi Y, et al. Statin therapy before transition to end-stage renal disease with posttransition outcomes. J Am Heart Assoc. 2019;8:e011869.
Fellström BC, Jardine AG, Schmieder RE, et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395-1407.
Vlad C, Burlacu A, Florea L, Artene B, Badarau S, Covic A. A comprehensive review on apolipoproteins as nontraditional cardiovascular risk factors in end-stage renal disease : current evidence and perspectives. Int Urol Nephrol. 2019;51(7):1173-1189.
Liu G, Bengtsson-Olivecrona G, Ostergaard P, Olivecrona T. Low-M(r) heparin is as potent as conventional heparin in releasing lipoprotein lipase, but is less effective in preventing hepatic clearance of the enzyme. Biochem J. 1991;273(3):747-752.
Wiemer J, Winkler K, Baumstark M, Marz W, Scherberich JE. Influence of low molecular weight heparin compared to conventional heparin for anticoagulation during haemodialysis on low density lipoprotein subclasses. Nephrol Dial Transplant. 2002;17(12):2231-2238.
Lai KN, Ho K, Cheung R, et al. Effect of low molecular weight heparin on bone metabolism and hyperlipidemia in patients on maintenance hemodialysis. Int J Artif Organs. 2001;24(7):447-455.
Signorelli SS, Scuto S, Marino E, Giusti M, Xourafa A, Gaudio A. Anticoagulants and osteoporosis. Int J Mol Sci. 2019;20(21). https://doi.org/10.3390/ijms20215275
Merli GJ, Groce JB. Pharmacological and clinical differences between low-molecular-weight heparins implications for prescribing practice and therapeutic interchange. P T. 2010;35(2):95-105.
Klingel R, Schwarting A, Lotz J, Eckert M, Hohmann V, Hafner G. Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis: results of an open-label post-certification study. Kidney Blood Press Res. 2004;27(4):211-217.
Dhondt A, Pauwels R, Devreese K, Eloot S, Glorieux G, Vanholder R. Where and when to inject low molecular weight heparin in hemodiafiltration? A cross over randomised trial. PLoS One. 2015;10(6):1-13.
Crowther MA, Berry LR, Monagle PT, Chan AKC. Mechanisms responsible for the failure of protamine to inactivate low-molecular-weight heparin. Br J Haematol. 2002;116(1):178-186.
Schroeder M, Hogwood J, Gray E, Mulloy B, Hackett AM, Johansen KB. Protamine neutralisation of low molecular weight heparins and their oligosaccharide components. Anal Bioanal Chem. 2011;399(2):763-771.
Xu Y, Cai C, Chandarajoti K, et al. Homogeneous low-molecular-weight heparins with reversible anticoagulant activity. Nat Chem Biol. 2014;10(4):248-250.
Lai S, Coppola B. Use of enoxaparin in end-stage renal disease. Kidney Int. 2013;84(3):433-436.
Brophy DF, Martin EJ, Gehr TWB, Carr ME. Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time. Am J Kidney Dis. 2004;44(2):270-277.
Lazrak HH, René E, Elftouh N, Lafrance JP. Association between low-molecular-weight heparin and risk of bleeding among hemodialysis patients: a retrospective cohort study. Can J Kidney Heal Dis. 2018;5. https://doi.org/10.1177/2054358118792010
Lord H, Jean N, Dumont M, Kassis J, Leblanc M. Comparison between tinzaparin and standard heparin for chronic hemodialysis in a Canadian center. Am J Nephrol. 2002;22(1):58-66.
Lim W, Cook DJ, Crowther MA. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials. J Am Soc Nephrol. 2004;15(12):3192-3206.
Lazrak HH, René É, Elftouh N, Leblanc M, Lafrance JP. Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: a systematic review and meta-analysis. BMC Nephrol. 2017;18(1):1-12.
Kronenberg F, König P, Neyer U, et al. Influence of various heparin preparations on lipoproteins in hemodialysis patients: a multicentre study. Thromb Haemost. 1995;74(04):1025-1028.
Kronenberg F, Konig P, Lhotta K, Steinmetz A, Dieplinger H. Low molecular weight heparin does not necessarily reduce lipids and lipoproteins in hemodialysis patients. Clin Nephrol. 1995;43(6):399-404.
Buturovic-Ponikvar J. Is regional citrate anticoagulation the future of hemodialysis? Ther Apher Dial. 2016;20(3):234-239.
Wright S, Steinwandel ULI, Ferrari P. Citrate anticoagulation using ACD solution A during long-term haemodialysis. Nephrology. 2011;16(4):396-402.
Apsner R, Buchmayer H, Lang T, et al. Simplified citrate anticoagulation for high-flux hemodialysis. Am J Kidney Dis. 2001;38(5):979-987.
Gubensek J, Orsag A, Ponikvar R, Buturovic-ponikvar J. Calcium mass balance during citrate hemodialysis: a randomized controlled trial comparing normal and low ionized calcium target ranges. PLoS One. 2016;1-14. https://doi.org/10.1371/journal.pone.0168593
Lin T, Song LI, Huang R, et al. Modified regional citrate anticoagulation is optimal for hemodialysis in patients at high risk of bleeding: a prospective randomized study of three anticoagulation strategies. BMC Nephrol. 2019;20(1):472. https://doi.org/10.1186/s12882-019-1661-y
Apsner R, Buchmayer H, Gruber D, Sunder-Plassmann G. Citrate for long-term hemodialysis: prospective study of 1,009 consecutive high-flux treatments in 59 patients. Am J Kidney Dis. 2005;45(3):557-564.
Singer RF, Williams O, Mercado C, et al. Regional citrate anticoagulation in hemodialysis: an observational study of safety, efficacy, and effect on calcium balance during routine care. Can J Kidney Heal Dis. 2016;1-10. https://doi.org/10.1186/s40697-016-0113-x
Gubenšek J, Kovač J, Benedik M, et al. Long-term citrate anticoagulation in chronic hemodialysis patients. Ther Apher Dial. 2011;15(3):278-282.
Kossmann RJ, Gonzales A, Callan R, Ahmad S. Increased efficiency of hemodialysis with citrate dialysate: a prospective controlled study. Clin J Am Soc Nephrol. 2009;4(9):1459-1464.
Leung KCW, Tai DJ, Ravani P, Quinn RR, Scott-Douglas N, MacRae JM. Citrate vs. acetate dialysate on intradialytic heparin dose: a double blind randomized crossover study. Hemodial Int. 2016;20(4):537-547.
Dellepiane S, Medica D, Guarena C, et al. Citrate anion improves chronic dialysis efficacy, reduces systemic inflammation and prevents Chemerin-mediated microvascular injury. Sci Rep. 2019;9(1):1-10.
Villa-Bellosta R, Hernández-Martínez E, Mérida-Herrero E, González-Parra E. Impact of acetate- or citrate-acidified bicarbonate dialysate on ex vivo aorta wall calcification. Sci Rep. 2019;9(1):1-7.
Jain N, Reilly RF. Clinical pharmacology of oral anticoagulants in patients with kidney disease. Clin J Am Soc Nephrol. 2019;14:278-287.
Linkins L-A, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia. Chest. 2012;141(2):e495S-e530S.
Wellborn-Kim JJ, Mitchell GA, Terneus WF, et al. Fondaparinux therapy in a hemodialysis patient with heparin-induced thrombocytopenia type II. Am J Heal Pharm. 2010;67:1075-1079.
Murray PT, Hursting MJ. Heparin-induced thrombocytopenia in patients administered heparin solely for hemodialysis. Ren Fail. 2006;28:537-539.
Fischer KG. Essentials of anticoagulation in hemodialysis. Hemodial Int. 2007;11(2):178-189.
Magnani HN. A review of 122 published outcomes of danaparoid anticoagulation for intermittent haemodialysis. Thromb Res. 2010;125(4):e171-e176.
Link A, Girndt M, Selejan S, Mathes A, Bohm M, Rensing H. Argatroban for anticoagulation in continuous renal replacement therapy. Crit Care Med. 2009;37(1):105-110.
Murray PT, Reddy BV, Grossman EJ, et al. A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Kidney Int. 2004;66:2446-2453.
Reddy BV, Grossman EJ, Trevino SA, Hursting MJ, Murray PT. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy. Ann Pharmacother. 2005;39:1601-1605.
Pöschel KA, Bucha E, Esslinger H-U, et al. Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis. Kidney Int. 2004;65:666-674.
Van Wyk V, Badenhorst PN, Luus HG, Kotze HF. A comparison between the use of recombinant hirudin and heparin during hemodialysis. Kidney Int. 1995;48:1338-1343.
Mahieu E, Claes K, Jacquemin M, et al. Anticoagulation with fondaparinux for hemodiafiltration in patients with heparin-induced thrombocytopenia: dose-finding study and safety evaluation. Artif Organs. 2013;37(5):482-494.
Krummel T, Scheidt E, Borni-Duval C, et al. Haemodialysis in patients treated with oral anticoagulant: should we heparinize? Nephrol Dial Transplant. 2014;29(4):906-913.
Hursting MJ, Murray T. Argatroban anticoagulation in renal dysfunction: a literature analysis. Nephron Clin Pract. 2008;109:c80-c94.
Sombolos KI, Fragia TK, Gionanlis LC, et al. Use of fondaparinux as an anticoagulant during hemodialysis: a preliminary study. Int J Clin Pharmacol Ther. 2008;46:198-203.
Safadi Jr S, Albright Jr RC, Dillon JJ, et al. Prospective study of routine heparin acute care inpatient practice. Kidney Int Reports. 2017;2(4):695-704.
Ivanovich P, Xu C, Kwaan H, Hathiwala S. Studies of coagulation and platelet functions in heparin-free hemodialysis. Nephron. 1983;33:116-120.
Guery B, Alberti C, Servais A, et al. Hemodialysis without systemic anticoagulation: a prospective randomized trial to evaluate 3 strategies in patients at risk of bleeding. PLoS One. 2014;9(5):e97187.
Stamatiadis D, Helioti H, Mansour M, Pappas M, Bokos J, Stathakis C. Hemodialysis for patients bleeding or at risk for bleeding, can be simple, safe, and efficient. Clin Nephrol. 2004;1:29-34.
Casati S, Moia M, Granziani G, et al. Hemodialysis without anticoagulants: efficiency and hemostatic aspects. Clin Nephrol. 1984;21(2):102-105.
Laville M, Dorval M, Fort Ros J, et al. Results of the HepZero study comparing heparin-grafted membrane and standard care show that heparin-grafted dialyzer is safe and easy to use for heparin-free dialysis. Kidney Int. 2014;86:1260-1267.
Morena M, Jaussent I, Chalabi L, et al. Biocompatibility of heparin-grafted hemodialysis membranes: impact on monocyte chemoattractant protein-1 circulating level and oxidative status. Hemodial Int. 2010;14:403-410.
Chanard J, Lavaud S, Kazes I, Vitry F, Rieu P. The clinical evaluation of low-dose heparin in haemodialysis: a prospective study using the heparin-coated AN69 ST membrane. Nephrology. 2008;23:2003-2009.
Wu X, Chen H. Clinical study of heparin-free hemodialysis with the inside of hollow fibers in dialyzer coated by human albumins. Nephron. 2002;92:925-928.
Huraib S, Tanimu D, Shaheen F, Hejaili F, Giles C, Pagayon V. Effect of vitamin-E-modified dialysers on dialyser clotting, erythropoietin and heparin dosage: a comparative crossover study. Am J Nephrol. 2000;20:364-368.
Kiaii M, Aritomi M, Nagase M, Farah M, Jung B. Clinical evaluation of performance, biocompatibility, and safety of vitamin E-bonded polysulfone membrane hemodialyzer compared to non-vitamin E-bonded hemodialyzer. J Artif Organs. 2019;22(4):307-315.
Lines SW, Carter AM, Dunn EJ, Lindley EJ, Tattersall JE, Wright MJ. A randomized controlled trial evaluating the erythropoiesis stimulating agent sparing potential of a vitamin E-bonded polysulfone dialysis membrane. Nephrol Dial Transplant. 2014;29:649-656.
Islam MS, Hassan ZA, Chalmin F, et al. Vitamin E-coated and heparin-coated dialyzer membranes for heparin-free hemodialysis: a multicenter, randomized crossover trial. Am J Kidney Dis. 2016;68(5):752-762.
Rydzewska-Rosolowska A, Gozdzikiewicz-Lapinska J, Borawski J, Koc-Zorawska E, Mysliwiec M, Naumnik B. Unexpected and striking effect of heparin-free dialysis on cytokine release. Int Urol Nephrol. 2017;49(8):1447-1452.
Meijers KI, Poesen R, Evenepoel P. Heparin-coated dialyzer membranes: is non-inferiority good enough ? Kidney Int. 2014;86:1084-1086.
Evenepoel P, Dejagere T, Verhamme P, et al. Heparin-coated polyacrylonitrile membrane versus regional citrate anticoagulation: a prospective randomized study of 2 anticoagulation strategies in patients at risk of bleeding. Am J Kidney Dis. 2007;49(5):642-649.
Skagerlind MS, Stegmayr BG. An evaluation of four modes of low-dose anticoagulation during intermittent haemodialysis. Eur J Clin Pharmacol. 2018;74:267-274.
Vanommeslaeghe F, De Somer F, Josipovic I, Boone M, Van Biesen W, Eloot S. Evaluation of different dialyzers and the impact of predialysis albumin. Kidney Int Reports. 2019;4:1538-1545.
Skagerlind M, Stegmayr B. Heparin albumin priming in a clinical setting for hemodialysis patients at risk for bleeding. Hemodial Int. 2017;21:180-189.
Frank RD, Mu U, Lanzmich R, Groeger C, Floege J. Anticoagulant-free Genius haemodialysis using low molecular weight heparin-coated circuits. Nephrol Dial Transplant. 2006;21:1013-1018.
Fransson F, Kyrk T, Skagerlind M, Stegmayr B. Rinsing the extra corporeal circuit with a heparin and albumin solution reduces the need for systemic anticoagulant in hemodialysis. Int J Artif Organs. 2013;36(10):725-729.
Lim JH, Kang KP, Lee S, Park SK, Kim W. Recurrent heparin-induced thrombocytopenia due to heparin rinsing before priming the machine in a hemodialysis patient: a case report. Hemodial Int. 2017;21:E30-E33.
Caruana RJ, Raja RM, Bush JV, Kramer MS, Goldstein SJ. Heparin free dialysis: comparative data and results in high risk patients. Kidney Int. 1987;31(6):1351-1355.
Gordon L, Perkins H, Richards V. Studies in regional heparinization. I. The use of simultaneous neutralization with protamine; preliminary studies. N Engl J Med. 1956;255(22):1025-1029.
Strobl K, Harm S, Weber V, Hartmann J. The role of ionized calcium and magnesium in regional citrate anticoagulation and its impact on inflammatory parameters. Int J Artif Organs. 2017;40(1):15-21.
Cronin RE, Reilly RF. Unfractionated heparin for hemodialysis: still the best option. Semin Dial. 2010;23(5):510-515.
Naumnik B, Pawlak K, Myśliwiec M. Different effects of enoxaparin and unfractionated heparin on some thrombogenesis markers during hemodialysis: a cross-over study. Thromb Res. 2009;123(4):631-636.
Pettigrew M, Soltys GIM, Bell RZ, et al. Tinzaparin reduces health care resource use for anticoagulation in hemodialysis. Hemodial Int. 2011;15(2):273-279.
Leung KCW, MacRae JM. Anticoagulation in CKD and ESRD. J Nephrol. 2019;32(5):719-731.
Al-Ali FS, Elsayed M, Khalifa S, et al. Successful use of a bivalirudin treatment protocol to prevent extracorporeal thrombosis in ambulatory hemodialysis patients with heparin-induced thrombocytopenia. Hemodial Int. 2016;20(2):204-207.
Young G, Yonekawa KE, Nakagawa P, Blain R, Lovejoy AE, Nugent DJ. Recombinant factor VIIa reverses the anticoagulant effects of argatroban, bivalirudin, fondaparinux, enoxaparin, and heparin as assessed ex vivo by thromboelastography. Blood Coagul Fibrinolysis. 2007;18(6):547-553.
Sanofi-Aventis. Lovenox (Enoxaparin Sodium Injection) [package insert]. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020164s110lbl.pdf. Accessed September 26, 2020
Johansen KB, Balchen T. Tinzaparin and other low-molecular-weight heparins: what is the evidence for differential dependence on renal clearance? Exp Hematol Oncol. 2013;2:21.
Pfizer. Fragmin (Dalteparin Sodium Injection) [package insert]. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020287s072lbl.pdf. Accessed September 26, 2020
Barradell L, Buckley M. Nadroparin calcium: a review of its pharmacology and clinial applications in the prevention and treatment of thromboembolic disorders. Drugs. 1992;44:858-888.
Celgene. Innohep (Tinzaparin Sodium Injection) [package insert]. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/020484s011lbl.pdf. Accessed September 26, 2020